Thalidomide induces amenorrhea in patients with lupus disease

Ordi, J; Cortés, Fina; Martínez, Núria; Mauri, M; Torres, Inés de; Vilardell, M

doi:10.1002/1529-0131(199812)41:12<2273::aid-art26>3.0.co;2-6

Cited by 39 publications

(12 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…30 More infrequent effects are neutropenia, hypothyroidism, 31,32 and secondary amenorrhea. 33 Some cutaneous side effects have been reported, eg, pruritus, facial edema, palmar erythema, 32 rash, 34 drug rash with eosinophilia and systemic symptoms, 35 and oral lichenoid lesions. 36 How thalidomide acts will remain uncertain as long as the pathophysiology of sarcoidosis is unclear.…”

Section: Discussionmentioning

confidence: 99%

Treatment of cutaneous sarcoidosis with thalidomide

Nguyen

Dupuy

Cordoliani

et al. 2004

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Treatment of cutaneous sarcoidosis with thalidomide

Nguyen

Dupuy

Cordoliani

et al. 2004

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…In 1989 Gutierrez‐Rodriquez et al (62) reported amenorrhea as a side effect of thalidomide therapy for refractory rheumatoid arthritis in a 33‐year‐old woman. In a 1998 case series of 18 patients with CLE, thalidomide was the suggested cause of amenorrhea in 4 of 13 women (63). Menses resumed 2–3 months after cessation of thalidomide therapy in these patients.…”

Section: Major Side Effectsmentioning

confidence: 98%

Thalidomide therapy for cutaneous lupus erythematosus: historical and practical considerations

LaDuca¹,

Herrmann

Gaspari³

2001

Dermatol Ther

View full text Add to dashboard Cite

Connective tissue diseases are notoriously difficult to treat and the cutaneous manifestations of lupus erythematosus (LE) can be severe, leading to significant and progressive disfigurement. Fortunately several modalities exist for the treatment of this condition. However, oftentimes patients manifest severe disease and are refractory to conventional treatment. Second‐ and third‐line agents used to treat cutaneous LE (CLE) can also exhibit many intolerable side effects. Thalidomide, a drug with a notorious past, has been found to be efficacious in the treatment of most of these patients. Response can be dramatic and patients are often maintained on thalidomide as a monotherapy. We review thalidomide's past, with a focus on its use in the treatment of CLE. We also discuss the practical issues involved in safely administering this drug, using three case histories. In conclusion, thalidomide is very effective in the treatment of CLE, however, prolonged use is often needed to maintain long‐term remission. Properly used, thalidomide is very safe, with minimal and mild side effects. However, proper implementation and monitoring is imperative to guard against known serious side effects of teratogenicity and neuropathy.

show abstract

“…Thalidomide therapy can result in constipation, fatigue, lack of energy, and bradycardia, but these signs may also be manifestations of hypothyroidism, and the authors recommend assessment of serum TSH levels before starting thalidomide and every 3 months afterwards or if the diagnosis of hypothyroidism is suspected. Secondary amenorrhoea has been reported in ten women treated with thalidomide for aphtosis or lupus [98][99][100][101]. The amenorrhoea occurred 4 -7 months following the start of treatment and resolved after the discontinuation of thalidomide.…”

Section: Endocrinological Disordersmentioning

confidence: 99%

Thalidomide: an old drug with new clinical applications

Laffitte¹,

Revuz²

2004

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Thalidomide has several targets and mechanisms of action: a hypnosedative effect, several immunomodulatory properties with an effect on the production of TNF-alpha and the balance between the different lymphocyte subsets and an antiangiogenic action. Thalidomide has been used in several cutaneous inflammatory disorders (e.g., erythema nodosum leprosum in lepromatous leprosy, cutaneous lupus erythematosus and severe aphtosis), cancers (e.g., relapsed/refractory multiple myeloma, malignant melanoma and systemic signs in cancer) and inflammatory conditions (e.g., Crohn's disease and rheumatoid arthritis). Several side effects are associated with thalidomide. Some are major, such as teratogenicity, peripheral neuropathy and deep vein thrombosis. Somnolence and rash are frequently reported when thalidomide is used at higher doses as an anticarcinogenic agent and can lead to dose reduction or treatment discontinuation depending on severity. Minor side effects include abdominal pain and endocrine disturbances. To prevent the teratogenicity, use of thalidomide is strictly controlled in western countries with close adherence to a birth control programme. Close monitoring for early development of peripheral neuropathy is also recommended.

show abstract

Thalidomide induces amenorrhea in patients with lupus disease

Cited by 39 publications

References 11 publications

Treatment of cutaneous sarcoidosis with thalidomide

Treatment of cutaneous sarcoidosis with thalidomide

Thalidomide therapy for cutaneous lupus erythematosus: historical and practical considerations

Thalidomide: an old drug with new clinical applications

Contact Info

Product

Resources

About